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Brain–blood barrier breakdownA breakdown of the brain–blood barrier (BBB) due to endothelial dysfunction is a primary feature of cerebralma-
laria (CM). Lipoxins (LX) are specialized pro-resolvingmediators that attenuate endothelial dysfunction in differ-
ent vascular beds. It has already been shown that LXA4 prolonged Plasmodium berghei-infectedmice survival by a
mechanism that depends on inhibiting IL-12 production and CD8+IFN-γ+T cells in brain tissue; however, the ef-
fects of this treatment on endothelial dysfunction induced during experimental cerebral malaria (ECM) remains
to be elucidated. Herein, we investigate the role of LXA4 on endothelial dysfunction during ECM. The treatment of
P. berghei-infectedmice with LXA4 prevented BBB breakdown and ameliorated behavioral symptoms but did not
modulate TNF-α production. In addition, microcirculation analysis showed that treatment with LXA4 signiﬁcant-
ly increased functional capillary density in brains of P. berghei-infected C57BL/6 mice. Furthermore, histological
analyses of brain sections demonstrated that exogenous LXA4 reduced capillary congestion that was accompa-
nied by reduced ICAM-1 expression in the brain tissue. In agreement, LXA4 treatment of endothelial cells stimu-
lated by Plasmodium berghei (Pb)- or Plasmodium falciparum (Pf)-parasitized red blood cells (RBCs) inhibited
ICAM-1 expression. Additionally, LXA4 treatment restored the expression of HO-1 that is reduced during ECM.
As well, LXA4 treatment inhibits PbRBC and PfRBC adhesion to endothelial cells that was reversed by the use of
anHO-1 inhibitor (ZnPPIX). Our results demonstrate for theﬁrst time that LXA4 ameliorates endothelial dysfunc-
tion during ECM by modulating ICAM-1 and HO-1 expression in brain tissue.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Malaria is the most widespread parasitic disease, and despite the
many efforts made to eradicate malaria, it still accounts for 1 million
deaths per year [1]. Death by cerebral malaria is closely associatedarrier; BOC-2, N-Boc-Phe-Leu-
; CM, cerebralmalaria; ECM, ex-
o sorbent assay;HO, heme oxy-
lipoxin; NO, nitric oxide; Pb,
odcell; TNF, tumornecrosis fac-
harmacology, Farmanguinhos,
iques).with the adhesion of parasitized erythrocytes to brain vasculature and
breakdown of the blood–brain barrier (BBB) [2,3]. In fact, it has been
widely demonstrated that murine experimental cerebral malaria
(ECM)-induced endothelial dysfunction depends on the adhesion of
parasitized erythrocytes to cerebral microvasculature [4–6]; the pro-
duction of inﬂammatory mediators, such as TNF-α, as well as increased
expression of adhesion molecules on endothelial cells [7,8]. Recent ad-
vances concerning malaria treatment have suggested that an adjuvant
therapy targeting endothelial activation improves patient outcome
[9–11]. Indeed, prevention of BBB disruption has been shown to dimin-
ish ECM [3], which can be achieved viapharmacological induction of the
stress-responsive protein heme oxigenase-1 (HO-1) and exposure to
carbon monoxide, the end-product of HO-1 activity [12].
Lipoxins (LX) are products of arachidonic acid metabolism and are
produced through sequential lipoxygenase activity following cell–cell
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tion of LXA4 and its receptor, ALX has an anti-inﬂammatory and pro-
resolving activity in several inﬂammatory models such as allergic air-
way inﬂammation [14], autoimmune diseases [15] and inﬂammatory
diseases triggered bybacterial infection [16]. The effect of LXA4 on endo-
thelial cells includes the stimulation of cytoprotective pathways
[17–20]. It has been widely reported that LXA4 upregulates the expres-
sion of heme-oxygenase 1 (HO-1), a stress-responsive enzyme with
cytoprotective activities [21]. In fact, the stimulation of HO-1 expression
by LXA4 in endothelial cells is responsible for the inhibition of cellular
activation, including decreased expression of adhesion molecules [22].
Recently, Shryock and colleagues [23] demonstrated that, during se-
vere malaria, treatment with LX epimers (15-epi-LXA4) prolonged sur-
vival by a mechanism that depends on inhibiting IL-12 production and
CD8+IFN-γ+ T cell accumulation in brain tissue. However, the effects
of this treatment on endothelial dysfunction that is triggered during
ECM remain to be elucidated. In the present study, we provide evidence
that LXA4 exerts a protective effect on brain's endothelial cells by bene-
ﬁcially impacting cerebral edema formation and microcirculation. The
underlying mechanisms are shown to include the prevention of capil-
lary rarefaction and anti-adhesive/anti-inﬂammatory effects on endo-
thelial cells.
2. Materials and methods
2.1. Ethics statement
This work was carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocol was approved by the
Committee on Ethical Use of Laboratory Animals of the Oswaldo Cruz
Foundation (permit number L052/12).
2.2. Animal preparation and experimental protocol
Male C57BL/6 mice (5–6 weeks old) were provided by the Oswaldo
Cruz Foundation breeding unit (Rio de Janeiro, Brazil) and caged
with free access to food and fresh water at the Farmanguinhos experi-
mental facility, with a room temperature ranging from 22 to 24 °C in a
12-hour light/dark cycle. The animals were randomly assigned to
three groups: uninfected, P. berghei-infected and LXA4-treated
P. berghei-infected mice. P. berghei ANKA GFPcon 259cl2 was donated
from Malaria Research and Reference Reagent Resource Center (MR4,
Manassas, VA; deposited by CJ Janse and AP Waters, MR4 number:
MRA-865). The infection was induced via intraperitoneal (i.p.) injection
of 5 × 106 P. berghei-parasitized red blood cells (PbRBCs) diluted in sa-
line solution (200 μl),whichwerewithdrawn fromapreviously infected
mouse of the same strain. Uninfected animals received saline solution
(200 μl, i.p.). LXA4 treatment (0.5 μg/kg/day in 200 μl sterile saline)
was performed by i.p. injection 2 h before infection. Untreated mice re-
ceived the same volume of sterile saline. The treatment was performed
daily, from day 1 to day 6 post-infection. Six days post-infection, a thick
blood smear was performed for parasitemia determination using Diff-
Quick staining. ECM was deﬁned as the presentation of at least 2 of
the following clinical signs of neurologic involvement: ataxia, limb pa-
ralysis, poor righting reﬂex, seizures, roll-over and coma. In addition, a
set of 6 behavioral tests (transfer arousal, locomotor activity, tail eleva-
tion, wire maneuver, contact righting reﬂex, and righting in arena)
adapted from the SHIRPA protocol [24,25] was used to provide a better
estimate of the overall clinical status of the mice during infection. The
performance in each test was assessed using the following scoring sys-
tem: 0 to 5 (transfer arousal), 0 to 4 (locomotor activity), 0 to 4 (tail el-
evation), 0 to 4 (wire maneuver), 0 to 3 (contact righting reﬂex), and 0
to 3 (righting in arena). Tests were performed at day 0 and day 6 post-
infection in 10 mice per group. The data are expressed as differences
between the values registered at day 0 (pre-infection) and day 6 post-infection, from each individual mouse. Lower numbers represent maxi-
mum performance, whereas higher scores represent severe behavioral
impairment. During all experimental of the procedures, the mice were
monitored daily, and those that presented impaired locomotor activity
and no struggle response to sequential handling were euthanized.2.3. TNF-α determination from brain tissue
TNF-α levels were evaluated from brain tissue. Brieﬂy, brains from
non-infected, P. berghei-infected and LXA4-treated P. berghei-infected
mice were excised and homogenized in cell lysis buffer [20 mM TRIS,
150 mM NaCl, 5 mM KCl, 1% Triton X-100, protease inhibitor cocktail
(1:1000, Sigma-Aldrich, USA)] and immediately frozen at−80 °C. The
total protein content of each tissue homogenate was evaluated using
the Bradford method, followed by determination of cytokine production
using a standard sandwich ELISA, performed according to manufacturer's
instructions (BD Pharmingen, USA). The plates were read at 490 nm in
M5 Spectrophotometer (Molecular Devices, USA). The results were
expressed as ng of cytokine per mg of tissue.2.4. Evaluation of blood–brain barrier disruption
BBB disruptionwas evaluated as previously described [26]. Themice
were infected and treated as described above. On day 5 post-infection,
mice received an intravenous (i.v.) injection of 1% Evans blue dye
(Sigma-Aldrich, Brazil) and were euthanized 1 h later. Their brains
were weighed and placed in formamide (2 ml, 37 °C, 48 h) to extract
the Evans blue dye from the brain tissue. Absorbance was measured at
620 nm (Spectramax 190, Molecular Devices, CA, USA). The concentra-
tion of Evans blue dye was calculated using a standard curve. The data
are expressed as mg of Evans blue dye per g of brain tissue.2.5. Cerebral intravital microscopy with epi-illumination and ﬂuorescence
For intravital microscopy, the mice were infected and treated as
described above. At day 5 post-infection, they were anesthetized via
i.p. injection with a mixture of ketamine (100 mg/kg) and xylazine
(10 mg/kg). Anesthesia was maintained via additional intravenous
(i.v.) doses of 5mg/kg via the tail vein. Core temperaturewasmonitored
with a rectal probe and was maintained at 37 °C with a homeothermic
blanket (Harvard Apparatus, Boston, MA, USA).
To visualize the cerebral microcirculation, a craniotomy of the right
parietal bonewas performed using a drill to expose the piamatermicro-
vasculature, as described previously [27]. This window also enables vi-
sualization of in vivo leukocyte recruitment [28]. The assessed ﬁeld
was continuously perfused with artiﬁcial cerebrospinal ﬂuid at 37 °C,
pH 7.35. The perfusate was continuously aerated with 10% O2, 6% CO2
and 84% N2 tomaintain tension and gas levels comparable to physiolog-
ical pH and to avoid local inﬂammation.
Following i.v. administration of ﬂuorescein dextran (FITC-dextran
150), images of the microcirculation were acquired using Archimed
3.7.0 software (Microvision, Evry, France). The capillary count was
made using Saisam 5.1.3 software (Microvision). Serial images were
taken with 10× ocular and 10× objective lenses (Olympus BX150WI;
Center Valley, PA, USA) for 1min/ﬁeld from four ﬁelds. Only the contin-
uously perfused capillaries were counted to determine the mean func-
tional capillary density, expressed as the number of capillaries/mm2.
To label circulating leukocytes, 0.3 mg/kg rhodamine 6G was i.v.
injected. Fluorescing leukocytes were visualized viamicroscopy as de-
scribed above. The leukocyte–endothelial interaction was evaluated by
counting the number of leukocytes adhering to the venular wall
(100 μm long) over 30 s and expressed as the number of cells/min/
100 μm. Parameters were determined in pia mater venules with diame-
ters ranging from 50 to 70 μm.
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Brains from uninfected, P. berghei-infected and LXA4-treated
P. berghei-infected mice were carefully removed, ﬁxed in 4% buffered
formaldehyde, and parafﬁn-embedded. Five-micrometer-thick slices
were cut and stained with hematoxylin and eosin. The cerebral micro-
vasculature was analyzed in the cortical-medullary region. Occlusive
vessels were examined in 30 consecutive ﬁelds under 400× magniﬁca-
tion. Adhered parasitized red blood cells were assessed in 30 consecu-
tive ﬁelds under 1000× magniﬁcation according to the following
semi-quantitative scoring: 0 = no adhered parasitized red blood cells;
1 = unique adhered parasitized red blood cells; 2 = adhered rosettes;
3 = diffuse adhered cells.2.7. Immunodetection of HO-1 and ICAM-1
Brains were removed from perfused mice and homogenized in ice-
cold extraction buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40)
freshly supplemented with phosphatase and protease inhibitors
(10 mM NaF, 5 mM Na3VO4, 5 mM Na4P2O7 and 1× protease inhibitor
cocktail, Sigma-Aldrich, USA). The ﬁnal protein concentration in
each condition was determined using the DC™ Protein assay reagent
(Bio-Rad, USA), using BSA as a standard. Aliquots containing 30 μg of
protein were re-suspended in SDS-PAGE loading buffer, resolved on
11% SDS acrylamide gels and transferred onto PVDF Hybond™
membranes (Amersham, UK). After blocking with 5% non-fat dry
milk/Tris-buffered saline containing 0.1% Tween-20 for 1 h at room
temperature, the membranes were probed overnight at 4 °C with spe-
ciﬁc primary antibodies followed by horseradish peroxidase-labeled
secondary antibodies. Rabbit polyclonal anti-mouse HO-1 (1:5000)
and horseradish peroxidase-labeled goat polyclonal anti-rabbit anti-
bodies (1:2500) were obtained from Enzo Life Sciences, Inc. (USA).
Mouse monoclonal anti-mouse ICAM-1 (1:1000) and horseradish
peroxidase-labeled goat monoclonal anti-mouse antibodies (1:500)
were obtained from Santa Cruz Biotechnologies, Inc. (USA). Then,
PVDF sheets were incubated with streptavidin-conjugated horseradish
peroxidase (1:10,000) for 1 h and developed by an ECL®-plus reagent
(Enhanced Chemiluminescence, Amersham Biosciences). The bands
were quantiﬁed by densitometry, using ImageJ (public domain) soft-
ware programs.
The probed membranes were stripped with Re-Blot Plus Western
Blot stripping solution (Millipore) for 30 min at room temperature
and re-probed with rabbit polyclonal β-actin antibody to detect total
levels of protein.2.8. Endothelial cell stimulation
The murine thymic endothelioma cell line (tEnd.1) [29] and the
human endothelial cell line ECV-304 [22] were kindly provided by
Dr. T.C. Barja-Fidalgo (Universidade do Estado do Rio de Janeiro,
Brazil). The endothelial cell lines ECV-304 or tEnd.1 were cultured in
RPMI-1640 medium supplemented with 10% heat-inactivated FBS,
2 mM L-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin.
The cells were plated onto 24-well culture plates (Nunc, Rochester,
NY, USA) and incubated (104 cells/well) at 37 °C in a humidiﬁed incuba-
tor containing 5% CO2 chambers for 24 h. Before each experiment, ECV-
304 or tEnd.1 cells were pretreated or notwith LXA4 (10 nM) for 1 h, the
LXA4 receptor antagonist BOC-2 (N-Boc-Phe-Leu-Phe-Leu-Phe, 40 nM)
or the HO-1 inhibitor zinc protoporphyrin IX (ZnPPIX, 50 μM).
P. falciparum-infected RBCs (PfRBCs, kindly provided by Dr. M.G. Zalis,
Universidade Federal do Rio de Janeiro) or P. berghei-infected RBCs
(PbRBCs) were stained with CFSE (25 μM; Life Technologies, USA) for
30 min and then added to both non-treated or treated the ECV-304 or
tEnd.1 cultures (50 erythrocytes/cell, 5% parasitemia).2.9. Cytoadherence assay
ECV-304 and tEnd.1 cells were cultured and treated as de-
scribed above, and PfRBCs or PbRBCs were allowed to adhere to
the ECV-304 or tEnd.1 cultures for 1 h. Non-adherent erythrocytes
were gently washed away with PBS, and the remaining cells were
subsequently ﬁxed in ethanol and stained with Giemsa (Merck,
Brazil). The number of adhered erythrocytes per ECV-304 or
tEnd.1 cell was determined by direct counting under 400× magni-
ﬁcation. The data are expressed as an association index calculated
as previously described [30]: Adhesion index (AI) = (cell with
bound erythrocytes) / total cell number × (erythrocytes bound to
cell) / (total cell number × 100).2.10. Immunocytochemistry
ECV-304 or tEnd.1 pre-treatment and stimulation were performed
as described above. The immunoﬂuorescent studies were performed
as described previously [26]. To evaluate ICAM-1 expression, cells
were ﬁxed with 4% (w/v) paraformaldehyde and 4% (w/v) sucrose,
followed by blocking with 2% bovine serum albumin. The cells were
then incubated with anti-human ICAM-1 (1:50, BD Pharmingen, USA)
mAb or anti-mouse ICAM-1 (1:100 BD Pharmingen, USA) and subse-
quently incubated with the appropriate secondary FITC-conjugated an-
tibody (Santa Cruz Biotechnology, USA). Microscopic acquisition of the
ﬂuorescent images was performed using a ﬂuorescence microscope
(Nikon, Japan), and the ﬂuorescence intensity was measured using
Volocity software (Perkin Elmer, USA).2.11. Statistical analysis
Statistical signiﬁcance was assessed using ANOVA followed by the
Bonferroni test. The results are expressed as the mean ± SEM, and the
signiﬁcance level in all cases was set at p ≤ 0.05. A log-rank (Mantel–
Cox) test was used to compare the percent survival. The signiﬁcance
level was set at p ≤ 0.05.3. Results
3.1. LXA4 prevents cerebral dysfunction induced by P. berghei infection
independently of TNF-α production
To address the involvement of LXA4 on vascular dysfunction
during ECM P. berghei-infected C57BL/6 mice were treated with LXA4
(0.5 μg/kg/day). Initially, LXA4 dose-response curves were constructed,
and from these curves the threshold dose was deﬁned (Supplemental
data 1). LXA4 treatment did not alter parasitemia levels 5 d post-
infection (Fig. Fig. 1A), however, in agreement with a previous study
[23], prolonged the survival of P. berghei-infected mice (Fig. Fig. 1B).
Treatment with LXA4 reduced the Evans blue dye extravasation into
brain tissue observed during ECM (Fig. Fig. 1C). It is important to note
that treatment with LXA4 did not modulate Evans blue dye extravasa-
tion to the brain tissue of uninfected mice (Supplementary data 2).
Moreover, LXA4 treatment further improved behavioral and functional
scores in treated mice compared with untreated mice (Fig. Fig. 1D).
To investigate if LXA4 ameliorates vascular dysfunction by modulating
TNF-α production that accounts for activation of endothelial cells,
we investigated TNF-α production in brain tissue of LXA4 treated
P. berghei-infected mice. A signiﬁcant increase in TNF-α production
was observed in the brains of P. berghei infected C57BL/6 mice com-
pared to uninfected mice, however, the increased levels of TNF-α in-
duced by P. berghei infection were not affected by LXA4 treatment
(Fig. Fig. 1E).
Fig. 1. LXA4 attenuates cerebralmalaria. (A) Parasitemia levelswere evaluated 5 days post-infection in C57BL/6 infectedwith P. berghei and treatedwith LXA4 (0.5 μg/kg/day), as described
inMaterials andmethods. The results are expressed as themean± SEM from at least six animals per group in two independent experiments. (B) Survival rates for C57BL/6mice infected
with P. berghei untreated (vehicle, closed symbols) or treated with LXA4 (0.5 μg/kg/day, open circle). The log-rank test revealed signiﬁcantly different survival curves when untreated
P. berghei-infected (n = 10) and LXA4-treated P. berghei-infected (n = 10) C57BL/6 mice were compared (p = 0.04). (C) Evans blue dye extravasation within brain tissue from C57BL/
6 mice uninfected (open bars) or P. berghei-infected (closed bars) 5 days prior. C57BL/6 mice were treated with LXA4 (0.5 μg/kg/day). The results are expressed as the mean ± SEM
from at least six animals per group in two independent experiments. (D) Behavioral and functional analyses were evaluated 5 days post-infection in C57BL/6 infected with P. berghei
and treated with LXA4 (0.5 μg/kg/day), as described in Materials and methods. The results of behavioral and functional analyses are expressed as differences between values registered
pre- and post-infection (Δ) from at least six animals per group. (E) TNF-α levels from brain tissue were evaluated using ELISA. The results are expressed as the mean ± SEM of six
animals per group. Statistically signiﬁcant differences compared with the uninfected group (p b 0.05) are indicated by *, and statistically signiﬁcant differences compared with the
P. berghei-infected group (p b 0.05) are indicated by +.
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Accordingly, a signiﬁcant decrease in functional capillary density
was observed due to diminished numbers of spontaneously perfused
capillaries in the brains of P. berghei-infected mice (Fig. Fig. 2A and C)
compared to uninfected mice (Fig. Fig. 2A and B). This phenomenon
was partially reversed in LXA4-treatedmice (Fig. Fig. 2A and D). Accord-
ingly, histological analyses of brain sections from infected mice treated
with LXA4 showed a reduction in the number of congested capillaries
(Fig. Fig. 2E and H) compared to non-treated infected mice
(Fig. Fig. 2E and G). In histological analyses of brain sections from unin-
fected mice it was not observed glial cell swelling neither capillary con-
gestion (Fig. Fig. 2E and F). The diminished percentage of occluded
vessels observed in LXA4-treated mice was accompanied by lower
score of parasitized erythrocytes adhesion to brain vasculature
(Fig. Fig. 2I and L) then score observed in brain tissue of non-treated in-
fected mice (Fig. Fig. 2I and K). No leukocytes were observed adhering
to brain vasculature of non-infected mice (Fig. Fig. 2J).
3.3. LXA4 inhibits endothelial activation markers during ECM
To investigate if the effects of LXA4 are dependent of endothelial cell
activation, the expression of endothelial activation marker ICAM-1 wasquantiﬁed in brain tissue of P. berghei infected mice, treated or not
treated with LXA4. As expected, ICAM-1 expression was higher in
P. berghei infectedmice than in uninfectedmice, and LXA4 treatment re-
duced ICAM-1 expression in the brains of P. berghei-infected mice
(Fig. Fig. 3A). Corroborating such results, the co-culture ofmurine endo-
thelial cells (tEnd.1 cells) and red blood cells parasitized by P. berghei
(PbRBCs) induced the expression of ICAM-1 expression (Fig. Fig. 3B).
In agreement, P. falciparum-infected red blood cells (PfRBCs) also in-
duced ICAM-1 expression in human endothelial cells (ECV-304 cells)
(Fig. Fig. 3C). Interestingly, the treatment of both endothelial cell lines
with LXA4 impaired ICAM-1 expression when compared with the
equivalent parasitized RBC-stimulated control group. Treatment with
BOC-2 reversed the decreased ICAM-1 expression induced by LXA4
(Fig. Fig. 3B and C).
3.4. LXA4 triggers cytoprotective pathways during ECM
To address the hypothesis that LXA4 triggers endothelial protective
effects during ECM, we evaluated a mechanism by which LXA4 amelio-
rates endothelial cell function in P. berghei-infected mice. To this end,
the expression of HO-1was quantiﬁed in brain tissue of P. berghei infect-
ed mice, treated or not treated with LXA4. Low levels of HO-1 were de-
tected in the brains of P. berghei infected mice when compared with
Fig. 2. LXA4 effects on brain vascular dysfunction during P. berghei infection. (A) Intravital microscopy was performed on brains from C57BL/6 mice either uninfected (open bars) or in-
fected with P. berghei (closed bars) 5 days prior and functional capillary density were analyzed. Representative images of pial vessels in uninfected mice (B), P. berghei-infected mice
(C) and P. berghei-infected and LXA4-treated (0.5 μg/kg/day; D). (E) The percentage of occluded vessels in brain sections recovered from uninfected (open bars), P. berghei-infected (closed
bars) and P. berghei-infected and LXA4-treated (0.5 μg/kg/day) C57BL/6 mice. (I) Semi-quantitative analysis of cell adhesion in brain vessels. Values are expressed as the mean of 30 con-
secutiveﬁelds per slide from6 animals in each group, and the score of erythrocyte adhesionwas deﬁned as described in theMaterials andmethods section. The results are expressed as the
mean±SEM fromat least six animals per group in two independent experiments. Statistically signiﬁcant differences comparedwith theuninfected group (p b 0.05) are indicated by *, and
statistically signiﬁcant differences compared with the P. berghei-infected group (p b 0.05) are indicated by+. Representative photomicrographs of brains from uninfected mice (F and J),
P. berghei-infectedmice (G and K) and P. berghei-infected and LXA4-treated (0.5 μg/kg/day; H and L) demonstrating occluded vessels (*), RBCs adhered to the endothelium (black arrows)
and leukocytes adhered to the endothelium (head arrows).
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levels of HO-1 over those observed in uninfected mice (Fig. Fig. 4A).
Additionally, the co-culture of endothelial cells and parasitized red
blood cells (either PbRBCs or PfRBCs) induced the adhesion of parasit-
ized RBCs to the membranes of the respective endothelial cells. Adhe-
sion was inhibited when both cell lines were pretreated with LXA4
(10 nM) and treatment with BOC-2 (40 nM) reversed the inhibitory ef-
fect of LXA4. To evaluate the mechanism by which LXA4 modulates par-
asitized RBC adhesion to endothelial cells, the cells were further treated
with ZnPPIX (50 μM) to block the activity of HO-1. We observed that
LXA4-reduced RBC adhesion was reversed by ZnPPIX pretreatment of
both endothelial cell lines (Fig. Fig. 4B and C, Supplementary data 2).4. Discussion
Herein, using an experimental model of cerebral malaria, we dem-
onstrate for the ﬁrst time that LXA4 exerts an endothelial protective ef-
fect during ECM by inducing cytoprotective pathways. Despite its
widely recognized role as anti-inﬂammatory mediator [13,19,31,32],the role of LXA4 during cerebral dysfunction induced by malaria infec-
tion is poorly understood.
Previous data in the literature have shown that treatment with the
LXA4 epimer improved mouse survival by inhibiting IL-12 production
and CD8+IFN-γ+ T cell accumulation in brain tissue [23]. In agreement
with these results, we observed amelioration of major signs of ECM as
cerebral edema and behavioral and functional scores. Interestingly,
when we performed a dose–response experiment aimed to pharmaco-
logically investigate the link between LXA4 levels and its effects, we ob-
served that lower doses were more effective. As described before, the
LXA4 receptor, ALX/FPRL, is a G-protein coupled receptor (GPCR) in-
volved in cell- and agonist-speciﬁc signaling [33]. Furthermore, ALX/
FRPL is regulated bydesensitization and agonist-induced internalization
[34]. Thus, in our model, where LXA4 is administered for 6 days, higher
doses of LXA4 are most likely inducing internalization and/or desensiti-
zation. In addition, LXA4 did not interfere with parasitemia levels,
supporting the evidence that LXA4 modulates exclusively the host re-
sponse to P. berghei infection.
Cerebral tissue damage induced during P. berghei infection is primar-
ily due to inﬂammatory cell accumulation/activation, the production of
Fig. 3. LXA4 inhibit ICAM-1 expression during P. berghei infection in vivo and in vitro.
(A) Representative membrane preparations of uninfected (lanes 1 and 2, open bars),
P. berghei-infected (lanes 3 and 4, closed bars) and P. berghei-infected and LXA4-treated
(0.5 μg/kg/day; lanes 5 and 6) underwent immunoblotting for the detection of ICAM-1 in
brain tissue. ICAM-1 expression levels were normalized to β-actin. The results are expressed
as the means ± SEM (n= 6) of two independent experiments. Statistically signiﬁcant differ-
ences comparedwith the uninfected group (p b 0.05) are indicated by *, and statistically signif-
icant differences comparedwith the P. berghei-infected group (p b 0.05) are indicatedby+. The
murine tEnd.1 endothelial cell line (B) and human ECV-304 endothelial cell line (C) were used
to determine ICAM-1 expression under parasitized RBC stimulation. ICAM-1 expression levels
were evaluated in endothelial cells pretreated with LXA4 (10 nM) or LXA4 plus BOC-2
(40 nM) and stimulated with parasitized (P. berghei— Pb; P. falciparum— Pf) RBCs. The results
are expressed as the MIF ± SEM from three independent experiments. Statistically signiﬁcant
differences compared with the parasitized RBC untreated group (p b 0.05) are indicated by
+, signiﬁcant differences comparedwith the LXA4 treated group are indicated by #, and signif-
icant differences between unstimulated and parasitized RBC-stimulated cells are indicated by *.
405M.C. Souza et al. / International Immunopharmacology 24 (2015) 400–407inﬂammatorymediators in the brain vasculature, and the breakdown of
the BBB. This latter effect is induced by decreased expression of junction
proteins in activated cerebral endothelial cells [3,35,36]. Lipoxins have
been described to ameliorate BBB breakdown in non-infectious experi-
mental models by modulating MMP9 expression and MAPK activation
[37,38]. Compelling evidence suggests that the protective role of LXA4
in diseases caused by apicomplexan parasites such as Toxoplasma gondii
[39,40] depends on inhibition of cytokine production. Accordingly, in-
creased production of IFN-γ and IL-12 has been demonstrated during
ECM in the absence of endogenous LXA4 [23]. It is noteworthy
that IFN-γ and IL-12 are more relevant in lymphocyte activation
rather than endothelial activation [41]. TNF-α has been demonstrated
as a crucial cytokine in endothelial dysfunction during ECM [42,43].
However, in our model, LXA4 did not modulate TNF-α production dur-
ing ECM. As well, LXA4 impairs the activation of TNF-α-stimulated en-
dothelial cells [22,44], which suggests that prevention of brain edema
formation in LXA4-treated mice does not depend on TNF-α production.
Although the modulation of cytokines by LXA4 treatment during severe
malaria cannot be excluded, our results concerning cerebral dysfunction
strongly suggested an additional role to the many played by this lipid
mediator in ECM.
Although we did not observe a difference in lymphocyte accumula-
tion in the brain tissue of LXA4-infected mice (data not shown), we ob-
served an improved functional capillary density, a signiﬁcant reduction
in vascular occlusion in the brains of LXA4-treated mice and reduced
P. berghei-infected erythrocytes adhered to brain vasculature. Indeed,
ECM is associatedwith vasoconstriction and impaired responses to ace-
tylcholine due to nitric oxide synthase dysfunction [45,46]. Thus, thera-
peutic approaches for improving endothelial function, such as the
induction of HO-1 expression and reduction of ICAM-expression
through the administration of either NO donors [47] or carbon monox-
ide [12], would be beneﬁcial in P. berghei infection.
To conﬁrm the hypothesis that LXA4 is acting on endothelial
dysfunction induced during ECM, the expression of endothelial cell acti-
vationmarker, ICAM-1, was investigated. In the current study, LXA4 im-
paired ICAM-1 expression in brain tissue of infected mice, as well as in
PbRBCs- and PfRBCs-stimulated endothelial cells in vitro. The ability
of the LXA4/ALX complex to modulate the expression of adhesion
molecules has been described in other non-infectious models, including
their capability to reduce the expression of ICAM-1 on TNF-α-
stimulated endothelial cells in vitro [48,49]. Under inﬂammatory condi-
tions, ICAM-1 signaling is involved in endothelial activation, the
rearrangement of the endothelial actin cytoskeleton, the regulation of
vascular permeability, and the transmigration of immune cells into the
brain parenchyma [50,51]. The essential role of ICAM-1 in cytoadherence
and vascular occlusion during ECM has been previously demonstrated
[26]; however, until now, the direct effect of LXA4 on the inhibition of
ICAM-1 expression during ECM had not been shown.
Several studies have described that LXA4-induced HO-1 expression
attenuates endothelial dysfunction both in vivo [52,53] and in vitro
[22,54]. HO-1 is an isoenzyme that catabolizes free heme released
under pathological conditions, especially in pathologies that are associ-
ated with intravascular hemolysis, such as burns, microangiopathy and
malaria. HO-1 expression is related to tissue protection [21]. Indeed, the
presence of HO-1 limits the damage induced during the inﬂammatory
response, and its pharmacological up-regulation helpsmaintain BBB in-
tegrity under pathological conditions in vivo and in vitro [55]. It has been
widely described that HO-1 inhibits the expression of several adhesion
molecules, especially ICAM-1 [56,57]. As well, the modulation of adhe-
sion molecules by LXA4 via HO-1 expression in TNF-α-stimulated cells
has already been demonstrated [22]. In addition, parasites export pro-
tein to erythrocyte membrane that allows parasitized red blood cell ad-
hesion to adhesion molecules expressed on endothelial cells [42,58].
During ECM, HO-1 is known to be differentially regulated in certain
tissues at different stages of the Plasmodium life cycle [12,59]. Further-
more, HO-1 production in brain tissue is associatedwithmouse survival,
Fig. 4. LXA4-inducedHO-1 attenuates endothelial dysfunction induced by parasitized RBCs. (A) Representativemembrane preparations of uninfected (lanes 1 and 2, open bars), P. berghei-
infected (lanes 3 and 4, closed bars) and P. berghei-infected and LXA4-treated (0.5 μg/kg/day; lanes 5 and 6) underwent immunoblotting for the detection of HO-1 in brain tissue. HO-1
expression levels were normalized to β-actin. The results are expressed as the means ± SEM (n = 6) of two independent experiments. Statistically signiﬁcant differences compared
with the uninfected group (p b 0.05) are indicated by *, and statistically signiﬁcant differences compared with the P. berghei-infected group (p b 0.05) are indicated by +. The adhesion
of PbRBCs (B) to tEnd.1 or PfRBCs (C) to ECV-304was calculated using the adhesion index as described in theMaterials andmethods section. Adhesion index was evaluated in endothelial
cells lines pretreatedwith LXA4 (10 nM), LXA4 plus BOC-2 (40 nM) and LXA4 plus ZnPPIX (50 μM)and stimulatedwith parasitizedRBCs. The results are expressed as themean±SEM from
three independent experiments. Statistically signiﬁcant differences compared with the parasitized RBC untreated group (p b 0.05) are indicated by +, signiﬁcant differences compared
with the LXA4 treated group are indicated by #.
406 M.C. Souza et al. / International Immunopharmacology 24 (2015) 400–407decreased cerebral edema and decreased ICAM-1 expression [12]. How-
ever, even though LXA4 has been demonstrated to induce HO-1 expres-
sion in non-infectious models in vivo [60], this effect has not been
previously demonstrated in a malaria model. Thus, in our model, LXA4
probably reduces the ICAM-1 expression by inducing the expression of
HO-1.
Collectively, the results of this study suggest that LXA4 attenuates ce-
rebral dysfunction by regulating the expression of ICAM-1 and HO-1
both in vivo and in vitro.
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